Outlook Therapeutics (OTLK) Revenue (2015 - 2025)

Outlook Therapeutics' (OTLK) quarterly Revenue came in at -$91787.0 in Q3 2025, down 106.1% quarter-over-quarter from $1.5 million in Q2 2025.

Analysis

Outlook Therapeutics (OTLK) Revenue (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has reported Revenue for 6 consecutive years, with -$91787.0 the latest figure, recorded in Q3 2025.

On a quarterly basis, Revenue changed N/A year-over-year to -$91787.0 in Q3 2025; TTM through Sep 2025 was $7.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.4 million, changed N/A from the prior year.
Revenue was -$91787.0 for Q3 2025 at Outlook Therapeutics, down from $1.5 million in the prior quarter.
Over five years, Revenue peaked at $1.5 million in Q2 2025 and troughed at -$91787.0 in Q3 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Amgen	211.73 Bn	197.74 Bn	7.24 Bn	10.05 Bn
2	Gilead Sciences	180.92 Bn	177.74 Bn	6.22 Bn	7.80 Bn
3	Vertex Pharmaceuticals	132.16 Bn	124.30 Bn	2.84 Bn	3.33 Bn
4	Regeneron Pharmaceuticals	82.89 Bn	74.90 Bn	3.93 Bn	4.29 Bn
5	Argenx Se	61.41 Bn	56.23 Bn	1.37 Bn	1.52 Bn
6	Moderna	53.99 Bn	48.85 Bn	52.00 Mn	145.00 Mn
7	Alnylam Pharmaceuticals	34.48 Bn	31.18 Bn	992.69 Mn	1.29 Bn
8	Biogen	31.15 Bn	29.86 Bn	1.96 Bn	2.74 Bn
9	Roivant Sciences	30.05 Bn	30.05 Bn	1.16 Mn	1.44 Mn
10	Outlook Therapeutics	88.06 Mn	76.82 Mn	-8,265.00	-

Historic Data

Download Data